THERAPY DOSSIER · th-6c80aaefae21

AZ31 (ATM kinase inhibitor), with AZD6738 (ATR kinase inhibitor) as comparator

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05450692 ↗PHASE3active not recruiting

LATIFY: Ceralasertib + Durvalumab vs Docetaxel in Advanced/Metastatic NSCLC

Advanced or Metastatic Non-Small Cell Lung Cancer

Enrolment: 594 · Results not recorded

NCT04298021 ↗PHASE2unknown

DDR-Umbrella Study of DDR Targeting Agents (incl. AZD6738) in Advanced Biliary Tract Cancer

Bile Duct Cancer · Chemotherapy Effect

Enrolment: 74 · Results not recorded

NCT04090567 ↗PHASE2recruiting

Overcoming PARP Inhibitor Resistance in BRCA Advanced Breast Cancer (Ceralasertib arm)

Advanced Breast Carcinoma · Metastatic Breast Carcinoma · Germline BRCA1/2

Enrolment: 60 · Results not recorded

NCT02937818 ↗PHASE2completed

Novel Combinations (incl. AZD6738 + olaparib) in Platinum Refractory ES-SCLC

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Enrolment: 72 · Results not recorded

NCT03740893 ↗PHASE2recruiting

PHOENIX DDR/Anti-PD-L1 Trial (AZD6738) in Residual TNBC

Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRD

Enrolment: 119 · Results not recorded

NCT03334617 ↗PHASE2active not recruiting

HUDSON Phase II Umbrella (incl. Ceralasertib) in NSCLC Post Anti-PD-1/PD-L1

Non-Small Cell Lung Cancer

Enrolment: 528 · Results not recorded

NCT05582538 ↗PHASE2recruiting

ATRiBRAVE Trial: Ceralasertib Priming + Durvalumab/Nab-Paclitaxel in TNBC

Triple Negative Breast Cancer Metastatic

Enrolment: 37 · Results not recorded

NCT04704661 ↗PHASE1active not recruiting

DS-8201a + ATR Inhibition (AZD6738/Ceralasertib) in HER2-Expressing Solid Tumors (DASH)

Advanced Malignant Solid Neoplasm

Enrolment: 51 · Results not recorded

NCT03022409 ↗PHASE1completed

Pre-Surgical DDR Agents (Ceralasertib + Olaparib) in HNSCC

Head and Neck Squamous Cell Carcinoma

Enrolment: 21 · Results not recorded

NCT06754761 ↗PHASE1not yet recruiting

Bioavailability and ADME of Ceralasertib (AZD6738) in NSCLC/Ovarian/Endometrial Cancer

Neoplasm

Enrolment: 8 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28145510 ↗2017Reported harm

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.

MouseRadiationC57BL/6J and Cdkn1a (p21) knockoutFemalen = Twelve groups of fifteen female C57BL/6 mice for survival;…Oral gavageAZ31 100 mg/kg and/or AZD6738 75 mg/kg, dosing volume 10 mL…2 h prior to total body irradiation

Model: Total body irradiation, 9 or 9.25 Gy delivered in a 137Cs irradiator at 67 cGy/min

ATM inhibition with AZ31 before total body irradiation reduced median time to moribund to 8 days, blocked p21 upregulation and G1 arrest and caused marked intestinal crypt loss, promoting gastrointestinal syndrome. ATR inhibition with AZD6738 did not shorten survival and increased p21 upregulation.

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…